Document is current
Any future updates will be listed below
-
Authors
Bruinsma, R. A.
Skogman, B. H.
van Hensbroek, M. Boele
Vermeeren, Y. M.
Hovius, J. W.
Zomer, T. P.
-
Funding
Funding for this research was provided by:
Science Fund of Gelre Hospitals, The Netherlands (2023.01)
- License Information
-
More Information
Article History
Received: 12 September 2024
Accepted: 20 May 2025
First Online: 2 July 2025
Declarations
:
: The study was approved by the Medical Ethics Committee of Isala hospital Zwolle, the Netherlands, and it was determined that the study falls outside the scope of the Dutch Medical Research Involving Human Subjects Act (number 230801). Children and/or parents (or guardians) provided written informed consent. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional review board and Medical Ethics Committee and with the Declaration of Helsinki.
: Not applicable.
: RB, BS, YV, TZ, MB declare that they have no competing interests. JH has ongoing research collaborations with Pfizer, Inc., and collaborates, or has collaborated, with Moderna, Antigen Discovery, Inc., Bio-Rad Laboratories, Abbott, and ZEUS Scientific on other projects on Lyme borreliosis. All agreements are between his institution (Amsterdam UMC) and the sponsor. JH has an application for a provisional patent related to Borrelia antigens pending.
